The Pharmaceutical Journal – A Royal Pharmaceutical Society publication reported yesterday after the findings of the The All Party Parliamentary Group (APPG) for Drug Policy Reform were published earlier in the week


The Royal Pharmaceutical Society says it would only back the use of cannabis as a licensed medicine if it is supported by clinical trial evidence. Its head of corporate communications, Neal Patel, says: “It’s right the potential of these ingredients should be explored through robust, high quality clinical trials to see if they can be developed into new, licensed medicines.

“Unless such trials prove the clinical benefit of cannabinoids, we do not support the medicinal use of cannabis, for example smoking or eating it,” he adds.  

Read full report at